UNSPSC 51111840: Cetrorelix

This classification denotes a gonadotropin releasing hormone inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OON1HFZ4BA. European Medicines Agency schedules Cetrorelix in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07459MIG. Cetrorelix generally arises in the molecular formula C70H92CLN17O14.

The term CETRORELIX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) CETRORELIX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cetrorelix under HS 29371900 and SITC 54154. As of Q4 2014, CETRORELIX remains the US FDA Preferred Term for this commodity. Cetrorelix bears US NLM identifiers UMLS ID C0209366 and NCI Concept Code C2481.

UNSPSC 51111840 Cetrorelix is a Commodity code naming a specific gonadotropin-releasing hormone (GnRH) antagonist pharmaceutical used in reproductive medicine and fertility treatment protocols. State and local governments procure this drug primarily through public health departments, correctional health services, family planning clinics, and hospital systems that provide reproductive health care to eligible populations. The drug is typically sourced through state pharmaceutical contracts, group purchasing organizations (GPOs), or direct vendor agreements negotiated at the state or regional level rather than through individual procurement notices.

The source provides no recent state and local contract opportunities or solicitations under this code. Without posted RFPs, RFQs, IFBs, or ITBs naming cetrorelix as a line item or primary scope, geographic distribution and issuing-body activity cannot be characterized from current procurement signals. Buyers evaluating this code should check state health department pharmaceutical formularies, correctional health procurement records, and GPO master agreements as alternative sources of demand signals, since pharmaceutical commodities often flow through standing contracts and cooperative purchasing arrangements that do not generate individual solicitation notices.